

Index

Note: Page numbers of article titles are in **boldface** type.

A

ABCB1 protein, gene polymorphisms of, 415–416

Adhesion molecules, gene polymorphisms of, 461, 464

Anergy, in tolerance, 386

B

Basiliximab, 475

Biomarkers, for gene polymorphisms, 412

BX471, for rejection prevention, 449

C

Carboxy-fluorescein diacetate succinimidyl ester test, for tolerance, 391

CCLs. *See* Chemokines and chemokine receptors.

Chemokines and chemokine receptors
gene polymorphisms of, 457, 460–462
immunosuppressive agent action
against, 476

in rejection, **441–454**
animal studies of, 446–448
antagonists for, 448–450
dendritic cell trafficking and,
375–384

description of, 442–443
mechanisms of, 443–446
nomenclature of, 442–443

Chimerism, in tolerance, 386–387

Clonal deletion, in tolerance, 386

Corticosteroids
actions of, 476
pharmacogenomics of, 414–415

Costimulation molecules, gene
polymorphisms of, 462–463

CSLCs. *See* Chemokines and chemokine
receptors.

CTLA-4 protein, gene polymorphisms of,
460–463

CXCLs. *See* Chemokines and chemokine
receptors.

Cyclosporine, 415–416, 475–476

Cytochrome P450 3A5, gene
polymorphisms of, 413–415

Cytokines, **469–479**. *See also specific
cytokines.*
actions of, 469–470
gene polymorphisms of, **423–440**,
456–459, 462
definition of, 424
in heart transplantation, 423,
425–435
in lung transplantation, 423,
435–436
immunosuppressive agent action
against, 475–476
in chemokine induction, 443–444
in rejection, 470–472
in tolerance, 473–475
intracellular, flow cytometry in,
369–370
T cells alloreactive to, enumeration of,
365–373

Cytotoxic T lymphocyte assay, for
tolerance, 390

D

Daclizumab, 475

Dendritic cell trafficking
donor versus recipient, 379–380
manipulation of, 380–381
pathways for, 376–377
tolerance and, 403

Dexamethasone, 475

E

ELISA (enzyme-linked immunosorbent
assay), for tolerance, 390

ELISPOT (enzyme-linked immunosorbent spot) assay
for T cell alloreactivity, 367–369
for tolerance, 390

F

Fas and FasL protein, gene polymorphisms of, 429, 431, 433, 435

Flow cytometry
for intracellular cytokines, 369–370
for tolerance, 391–392

FOXP3 protein, in tolerance, 397

FTY720 (sphingosine analog pro-drug), in dendritic cell manipulation, 380–381

G

Gene polymorphisms, **455–468**
of adhesion molecules, 464
of chemokines and chemokine receptors, 457, 460–462
of costimulation molecules, 462–463
of cytokines, **423–440**, 456–459, 462
definition of, 424
in heart transplantation, 423, 425–435
in lung transplantation, 423, 435–436
of growth factors, 463–464
of immunosuppressive agents, 413–417
pitfalls in literature, 464–465

GITR protein, in tolerance, 397

Glycoprotein, gene polymorphisms of, 415–416

Growth factors, gene polymorphisms of, **423–440**, 463–464
in heart transplantation, 423, 425–435
in lung transplantation, 423, 435–436

H

Heart transplantation, cytokine and growth factor gene polymorphisms in, 423, 425–435

I

ImmunoKnow test, for tolerance, 393

Immunologic assays, for tolerance, 388, 390–394

Immunophenotyping, for tolerance, 392–393

Immunosuppressive drugs

anticytokine actions of, 475–476
in dendritic cell manipulation, 380–381
pharmacogenomics of, **411–422**

Inosine monophosphate dehydrogenase, gene polymorphisms of, 416

Intercellular adhesion molecules
gene polymorphisms of, 461, 464
in rejection, 472

Interferon(s)
gene polymorphisms of, 424, 426, 428, 432, 434, 456–458
immunosuppressive agent action against, 476
in chemokine induction, 445
T cells alloreactive to, enumeration of, 366, 368, 370

Interferon gamma kinetics assay, for alloreactive T cells, 370–371

Interleukin(s)
gene polymorphisms of, 424, 426–434, 436, 456–457, 459
immunosuppressive agent action against, 475–476
in chemokine induction, 443–444
in rejection, 470–472
in tolerance, 473–475
T cells alloreactive to, enumeration of, 366

Intracellular cytokine staining test, for tolerance, 392

J

Janus kinases, antagonists against, 476

K

Kidney transplantation
cytokines in, alloreactive T cell enumeration in, **365–373**
immune gene polymorphisms in, **455–468**
tolerance in, monitoring for, **385–410**

L

Limiting dilution assay, for tolerance, 390

Liver transplantation
immune gene polymorphisms in, **455–468**
tolerance in, 399–400

Lung transplantation, cytokine and growth factor gene polymorphisms in, 423, 435–436

M

- MDR1 protein, gene polymorphisms of, 415–416
- Membrane transporters, gene polymorphisms of, 415–416
- Met-RANTES, for rejection prevention, 448–449
- Microarray analysis, for tolerance, 389, 395–405
- Mixed leukocyte reaction test, for tolerance, 390
- MRL-957, for rejection prevention, 449
- MRP2 protein, gene polymorphisms of, 415–416
- Mycophenolic acid, pharmacogenomics of, 415–418

N

- Natural killer cells, in tolerance, 403
- Neuropilin, in tolerance, 397

P

- P-glycoprotein, gene polymorphisms of, 415–416
- Pharmacogenomics, of immunosuppressive agents, **411–422**
 biomarkers for, 412
 complex effects of, 412
 for personalized therapy, 417–420
 gene polymorphisms in, 413–417
 therapeutic window of, 411–412
 variability of response and, 411
- Platelet-derived growth factor, gene polymorphisms of, 427, 433–434
- Polymerase chain reaction, for tolerance, 393
- Proteomics, in tolerance detection, 394

R

- RANTES, gene polymorphisms of, 460, 462
- Rapamycin, 380–381, 475
- Rejection, transplantation
 chemokines and chemokine receptors in, **441–454**
 cytokine-producing T cell enumeration in, **365–373**
 cytokines in. *See* Cytokines.
 dendritic cells in, **375–384**, 403

- gene polymorphisms in, 413–417, **423–440**, **455–468**
 microarray analysis in, **385–410**
 pharmacogenomics in, **411–422**

S

- Selectins, gene polymorphisms of, 461, 464
- Sirolimus, pharmacogenomics of, 414

T

- T cells
 alloreactive, enumeration of, **365–373**
 regulatory, in tolerance, 397, 473–475
- Tacrolimus, pharmacogenomics of, 413–415
- TeLandscape test, for tolerance, 392
- Tetramer test, for tolerance, 391
- Tolerance, transplant, **385–410**
 immunoassays for, 387–389
 mechanisms in, 386–387
 microarray analysis in, 389, 395–405
 monitoring strategies for, 390–394
 operational, 385–386
 pretransplant induction of, 387
- Toll-like receptors, gene polymorphisms of, 435–436
- Trans vivo delayed-type hypersensitivity assay, for tolerance, 391
- Transforming growth factor- β 1, gene polymorphisms of, 424, 427, 429–430, 432–434, 461, 463
- Transplantation. *See also specific organs.*
 rejection in. *See* Rejection.
- Tumor necrosis factor- α
 gene polymorphisms of, 424, 426, 428–430, 432, 434, 456–459
 in rejection, 472
 T cells alloreactive to, enumeration of, 366

U

- Uridine glycosyltransferases, gene polymorphisms of, 416

V

- Vascular endothelial growth factor
 gene polymorphisms of, 427, 429–431, 433–434, 461, 463–464
 in rejection, 472

W

- Warfarin, pharmacogenomics of, 419